P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

• Deyan Yosifov,
• Julia von Tresckow,
• Adam Giza,
• Sandra Robrecht,
• Christof Schneider,
• Billy Jebaraj,
• Daniel Mertens,
• Matthias Ritgen,
• Anke Schilhabel,
• Karl-Anton Kreuzer,
• Anna Maria Fink,
• Othman Al-Sawaf,
• Petra Langerbeins,
• Kirsten Fischer,
• Barbara Eichhorst,
• Michael Hallek,
• Hartmut Döhner,
• Stephan Stilgenbauer,
• Paula Cramer,
• Eugen Tausch

Affiliations

Deyan Yosifov

1 University Hospital Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Julia von Tresckow

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Adam Giza

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Sandra Robrecht

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Christof Schneider

1 University Hospital Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Billy Jebaraj

1 University Hospital Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Daniel Mertens

2 German Cancer Research Center, Cooperation Unit “Mechanisms of Leukemogenesis”, Heidelberg, Germany

Matthias Ritgen

6 University Hospital Schleswig-Holstein, Campus Kiel, Department of Hematology, Kiel, Germany

Anke Schilhabel

6 University Hospital Schleswig-Holstein, Campus Kiel, Department of Hematology, Kiel, Germany

Karl-Anton Kreuzer

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Anna Maria Fink

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Othman Al-Sawaf

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Petra Langerbeins

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Kirsten Fischer

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Barbara Eichhorst

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Michael Hallek

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Hartmut Döhner

5 University Hospital Ulm, Department of Internal Medicine III, Ulm, Germany

Stephan Stilgenbauer

1 University Hospital Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Paula Cramer

3 Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany

Eugen Tausch

1 University Hospital Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany